Acacia Mental Health

What Acacia Mental Health does

Acacia Mental Health (operating as Acacia Clinics) is a private California-based mental health provider founded in 2018 by Stanford Medicine alumni Dr. David Carreon (CEO) and Dr. Nathan Meng (COO) under parent company Zoe Healthcare, Inc. The company specializes in advanced neuromodulation treatments for treatment-resistant mental illness, with two physical clinics in Sunnyvale and Monterey, California, and a stated focus on treatment-resistant depression, anxiety, OCD, PTSD, bipolar disorder, ADHD, migraines, chronic pain, and smoking cessation. Approximately 43% of patients travel over 600 miles for treatment, indicating a national medical-tourism draw beyond the core Northern California base.

Name

Acacia Mental Health

Legal name

Acacia Mental Health

Website

https://acaciaclinics.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Mental Health Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (62142)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC)

akta.pro secondary industries

Psychiatry & Medication Management Platforms (HLALAEAB), Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM)

Keywords

• Tms therapy services
• Neuromodulation treatment
• Treatment-resistant depression
• Accelerated brain stimulation
• Esketamine nasal therapy

Headquarters

HQ city

Sunnyvale

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Treatment Services: Direct patient treatment revenue through insurance reimbursements and private pay arrangements. Standard TMS covered by most insurance providers; accelerated protocols (HOPE-TMS, SAINT) may require out-of-pocket payment. Clinic accepts most major insurance plans including TRICARE for veterans.
2. Insurance Reimbursement: Revenue from insurance billing including Aetna, Anthem, Cigna, Health Net, Medicare, Optum, United Healthcare, SCFHP. Cigna has removed prior authorization requirement for TMS as of March 2026.
3. Clinical Research Trials: Revenue from conducting sponsored clinical trials in partnership with academic institutions (Harvard, Brigham and Women's) and industry partners (Kernel, electroCore, Vagus Nerve Society). Studies provide TMS treatment at no cost to participants with compensation for time.
4. Private Pay / Self-Pay: Direct payment options for uninsured patients or those whose insurance does not cover specific treatments. Financial aid available for qualifying patients.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Acacia Clinics delivers advanced, non-invasive neuromodulation treatments—primarily Transcranial Magnetic Stimulation (TMS)—to patients with treatment-resistant depression and other mental illnesses. Its portfolio includes the proprietary HOPE-TMS® 5-day accelerated protocol, the FDA-cleared SAINT® neuromodulation system, conventional insurance-covered TMS, and SPRAVATO® (esketamine), supported by an in-house research center and a multidisciplinary clinical team of psychiatrists, nurse practitioners, psychologists, therapists, and a chaplain.

Product overview

Acacia Clinics is an industry-leading mental health provider offering a portfolio of advanced neuromodulation treatments for treatment-resistant mental illness. The core offering centers on Transcranial Magnetic Stimulation (TMS) therapies, including proprietary HOPE-TMS® (accelerated 5-day protocol with fMRI-guided personalization), SAINT® Therapy (FDA-cleared Stanford-developed system), and Conventional TMS (insurance-covered standard protocol). SPRAVATO® (esketamine nasal spray) provides an additional medication-based pathway for treatment-resistant depression. The company's integrated model combines these treatments with an in-house research center (Acacia Research Center) that conducts clinical trials, publishes peer-reviewed research, and collaborates with academic partners like Harvard and Brigham & Women's Hospital to continuously optimize treatment protocols.

Differentiator

Problem solved

Functional benefit

Products and services

• HOPE-TMS® Therapy Acacia's proprietary accelerated TMS protocol combining a 5-day intensive treatment course with fMRI-guided personalized neuronavigation (targets calculated by Dr. Shan Siddiqi) and evidence-based psychotherapy, designed for adults with treatment-resistant depression and other treatment-resistant mental illness.
• SAINT® Therapy FDA-cleared SAINT® (Stanford Accelerated Intelligent Neuromodulation Therapy) Neuromodulation System developed by Magnus Medical, delivering non-invasive magnetic stimulation on an accelerated 5-day timeline using structural and functional MRI to inform a proprietary algorithm for personalized brain stimulation targeting. Delivered commercially at Acacia as the first independent provider in Northern California.
• Conventional TMS Therapy Standard FDA-approved Transcranial Magnetic Stimulation delivered in 8-22 minute sessions once per day over an 8-10 week course depending on diagnosis protocol, covered by most major insurance providers (Aetna, Anthem, Cigna, Health Net, Medicare, Optum, United Healthcare, SCFHP).
• SPRAVATO® (Esketamine) FDA-approved nasal spray containing esketamine administered under medical supervision to treat adults with treatment-resistant major depressive disorder by targeting NMDA receptors in the brain for rapid symptom relief; initial phase involves twice-weekly dosing which may be reduced over time based on patient response. Covered by most insurance plans.
• Acacia Research Center (sponsored clinical trials and research services) In-house research division conducting sponsored clinical trials and publishing peer-reviewed research in collaboration with Harvard Medical School, Brigham and Women's Hospital, Magnus Medical, electroCore, Kernel, Vagus Nerve Society, and other partners. Provides TMS treatment to research participants at no cost with participant compensation.
• Multidisciplinary mental health care (psychiatry and therapy services) Clinical care delivered by Acacia's multidisciplinary team including psychiatrists, psychiatric nurse practitioners, clinical psychologists, licensed clinical social workers, and a clinical chaplain, integrated with TMS/SPRAVATO treatment plans for patients with depression, anxiety, OCD, PTSD, and related conditions.

Quantifiable outcome

• 77% response rate for HOPE-TMS therapy in treatment-resistant patients
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core, minor and foundational.

• Vagus Nerve SocietycoreStrategic or Co-development Partner · 1 February 2026Partnership for PTSD research initiative using gammaCore non-invasive vagus nerve stimulation (nVNS) device. Study led by Dr. Danielle DeSouza and Dr. Noah DeGaetano evaluating nVNS as adjunctive treatment for PTSD symptoms using CAPS-5 assessment. Funded by Vagus Nerve Society with devices provided by electroCore.
• electroCorecoreTechnology or Integration · 1 January 2026Partnership providing gammaCore nVNS devices for PTSD research study. electroCore is a medical technology company (Nasdaq: ECOR) specializing in non-invasive vagus nerve stimulation. FDA has granted Breakthrough Device Designation for gammaCore for PTSD treatment.
• KernelminorStrategic or Co-development Partner · 1 January 2025Kernel is funding a paid observational biomarker study at Acacia using Kernel Flow technology (time-domain functional near-infrared spectroscopy) to measure brain activity in real-time during TMS and Spravato treatment. Study reviewed by Advarra IRB.
• Harvard Medical School / Brigham and Women's HospitalcoreStrategic or Co-development Partner · 1 January 2024NIH-funded collaboration for TMS research study mapping brain circuitry connected to TMS targets that modify symptoms across multiple mental health conditions (MDD, GAD, OCD, Schizophrenia). Brigham and Women's team includes Dr. Shan Siddiqi who also serves as Acacia's Brain Targeting Specialist.
• Magnus MedicalcoreTechnology or Integration · 1 January 2021First independent treatment center to provide commercial SAINT® neuromodulation system developed by Magnus Medical. SAINT uses structural and functional MRI to inform proprietary algorithm for personalized brain stimulation targeting. FDA cleared system. Brandon Bentzley, MD PhD is co-founder and CSO of Magnus Medical.
• Stanford MedicinefoundationalStrategic or Co-development PartnerFounding members Dr. David Carreon and Dr. Nathan Meng are Stanford Medicine alumni. Acacia's accelerated TMS protocol was developed in part by Dr. Brandon Bentzley at Stanford University Medicine. Clinical results similar to Stanford trials. Ongoing relationship through Stanford Brain Stimulation Lab.
• Feeling Good Whole HealthminorChannel Partner/ Reseller/ DistributorPartner clinic in Fremont, CA offering Team CBT Therapy (Levels 1-5) in-person and virtual. Does not accept insurance. $100-$314 per 45-minute session.
• Feeling Good InstituteminorChannel Partner/ Reseller/ DistributorPartner in Mountain View, CA with providers across CA, TX, NY. 'Master Physicians' starting at $500/hour. Free consultations available. Referrals to Acacia for TMS treatment.
• Brightside HealthminorChannel Partner/ Reseller/ DistributorVirtual mental health provider available across the U.S. Accepts insurance. Free online assessment. Referrals as appropriate.
• Charlie HealthminorChannel Partner/ Reseller/ DistributorVirtual personalized treatment programs combining group therapy, individual therapy, and family therapy. Up to 9-12 treatment hours per week.
• Embark Behavioral HealthminorChannel Partner/ Reseller/ DistributorNationwide network for adolescent and young adult mental health. Outpatient, residential, and virtual programming. Local programs in Campbell and Walnut Creek, CA.
• NOCDminorChannel Partner/ Reseller/ DistributorOCD treatment specialist with therapists trained in Exposure and Response Prevention (ERP) therapy. Available in U.S. and internationally.

Scale indicators9 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Success TMS: Multi-state TMS clinic chain offering insurance-covered and accelerated protocols. Directly comparable business model treating treatment-resistant depression with similar outcome messaging.
• TMS Centers of America: Multi-state TMS provider network focused on treatment-resistant depression, anxiety, and OCD. Comparable service line, patient population, and payor-driven delivery model.
• Pacific Neuropsychiatric Specialists: Large outpatient psychiatric group in California and the Pacific Northwest offering TMS, esketamine, and interventional psychiatry. Direct regional overlap with Acacia's patient base and treatment modalities.
• Neuronetics (NeuroStar): Manufacturer of the leading FDA-cleared TMS device (NeuroStar) and operator of affiliated clinic programs. Comparable on TMS clinical delivery and clinical evidence generation; broader footprint.
• Greenbrook TMS: Largest U.S. operator of TMS clinics with 100+ treatment centers. Most direct comparison for Acacia on multi-site TMS rollouts, payor relationships, and treatment-resistant depression focus.
• Mindful Health Solutions: California-based TMS and psychiatry provider operating multiple clinics across the West Coast. Direct regional competitor with overlapping patient acquisition channels and payor mix.

Broad incumbents

• Amen Clinics: National psychiatric clinic chain using brain imaging (SPECT) to guide treatment of depression, ADHD, and trauma. Comparable on imaging-guided psychiatry, hospitality-focused clinic model, and multi-state outpatient delivery.
• Kaiser Permanente Behavioral Health: Integrated payer-provider offering TMS and esketamine within a closed network across California. Competes for in-network treatment-resistant patients and influences payor coverage policy for TMS in the region.

Emerging players

• Magnus Medical: Developer of the FDA-cleared SAINT protocol that Acacia licenses; led by Dr. Brandon Bentzley (Stanford). Core technology partner, but as Magnus scales its own commercial clinics it becomes a partial competitor.
• Field Trip Health: Former psychedelic and ketamine-assisted psychotherapy clinic chain with comparable hospitality-led mental health model. Earlier-stage scale but adjacent interventional psychiatry positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AcaciaClinics
• Facebookfacebook.com/AcaciaClinics
• LinkedInlinkedin.com/company/acaciaclinics

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acacia Mental Health